Dow Up0.36% Nasdaq Up0.12%

Keryx Biopharmaceuticals Inc. (KERX)

15.63 Down 0.55(3.40%) 4:00PM EDT
|After Hours : 15.63 Down 0.00 (0.02%) 4:56PM EDT
ProfileGet Profile for:
Keryx Biopharmaceuticals Inc.
750 Lexington Avenue
20th Floor
New York, NY 10022
United States - Map
Phone: 212-531-5965
Fax: 212-531-5961

Index Membership:N/A
Full Time Employees:88

Business Summary 

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Keryx Biopharmaceuticals Inc.

Corporate Governance 
Keryx Biopharmaceuticals Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 8. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 4; Compensation: 8.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Ron Bentsur , 48
Chief Exec. Officer, Director and Member of R&D Committee
Mr. James F. Oliviero CFA, 38
Chief Financial Officer, Principal Accounting Officer, Sec. and Treasurer
Mr. Gregory P. Madison , 46
Chief Operating Officer and Exec. VP
Ms. Lauren Fischer ,
Director of Investor Relations
Mr. Brian R. Adams ,
VP and Gen. Counsel
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders